Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CEP-32496

Known as: BRAF(V600E) Inhibitor CEP-32496 
An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
CEP-32496, also known as RXDX-105 or Agerafenib, is a new orally active inhibitor for the mutated v-raf murine sarcoma viral… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2017
2017
11583Background: Lung cancers driven by oncogenic RET fusions have lower response rates to targeted monotherapy such as… Expand
Is this relevant?
2014
2014
CEP-32496 is a novel, orally active serine/threonine-protein kinase B-raf (BRAF) (V600E) kinase inhibitor that is being… Expand
Is this relevant?
2014
2014
Mutations in the BRAF gene have been identified in approximately 7% of cancers, including 60-70% of melanomas and 4–16… Expand
Is this relevant?
2012
2012
Mutations in the BRAF gene have been identified in approximately 7% of cancers, including 60% to 70% of melanomas, 29% to 83% of… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 2
Is this relevant?
2012
2012
Mutations in the BRAF gene have been identified in approximately 7% of cancers, including 60% to 70% of melanomas, 29% to 83% of… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?